Tandem Diabetes Care Inc
NASDAQ:TNDM

Watchlist Manager
Tandem Diabetes Care Inc Logo
Tandem Diabetes Care Inc
NASDAQ:TNDM
Watchlist
Price: 37 USD 1.07% Market Closed
Market Cap: 2.4B USD
Have any thoughts about
Tandem Diabetes Care Inc?
Write Note

Tandem Diabetes Care Inc
Depreciation & Amortization

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Tandem Diabetes Care Inc
Depreciation & Amortization Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Depreciation & Amortization CAGR 3Y CAGR 5Y CAGR 10Y
Tandem Diabetes Care Inc
NASDAQ:TNDM
Depreciation & Amortization
$16.4m
CAGR 3-Years
6%
CAGR 5-Years
23%
CAGR 10-Years
16%
Becton Dickinson and Co
NYSE:BDX
Depreciation & Amortization
$2.3B
CAGR 3-Years
1%
CAGR 5-Years
0%
CAGR 10-Years
15%
Boston Scientific Corp
NYSE:BSX
Depreciation & Amortization
$1.2B
CAGR 3-Years
15%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Stryker Corp
NYSE:SYK
Depreciation & Amortization
$1B
CAGR 3-Years
2%
CAGR 5-Years
6%
CAGR 10-Years
11%
Abbott Laboratories
NYSE:ABT
Depreciation & Amortization
$3.2B
CAGR 3-Years
-3%
CAGR 5-Years
1%
CAGR 10-Years
7%
Intuitive Surgical Inc
NASDAQ:ISRG
Depreciation & Amortization
$497.9m
CAGR 3-Years
15%
CAGR 5-Years
22%
CAGR 10-Years
21%
No Stocks Found

Tandem Diabetes Care Inc
Glance View

Market Cap
2.4B USD
Industry
Health Care

Tandem Diabetes Care Inc., a prominent figure in the healthcare sector, has carved out a notable niche with its innovative diabetes management solutions. Founded in 2006 and headquartered in San Diego, California, the company has become a leader in providing advanced insulin pump technologies. Central to Tandem’s business model is their flagship product, the t:slim X2 Insulin Pump, a sleek and user-friendly device praised for its ease of use and functionality. Through meticulous engineering and design, Tandem has positioned itself at the forefront of modern diabetes management by enhancing user experience and integrating advanced technologies such as continuous glucose monitoring (CGM) compatibility, making diabetes care more dynamic and responsive. Revenue for Tandem Diabetes Care primarily flows from the sale of these insulin pumps, along with associated supplies and accessories, which are crucial for ongoing diabetes management. The company also generates income through software and technology upgrades. By offering a subscription-based model, Tandem ensures steady revenue from the continual acquisition of consumables and technology updates, fostering customer loyalty and long-term engagement. Their commitment to innovation and patient-centric solutions has not only allowed them to tap into a growing market of diabetes patients seeking improved quality of life but has also strengthened their competitive edge in a rapidly evolving healthcare landscape.

TNDM Intrinsic Value
45.58 USD
Undervaluation 19%
Intrinsic Value
Price

See Also

What is Tandem Diabetes Care Inc's Depreciation & Amortization?
Depreciation & Amortization
16.4m USD

Based on the financial report for Sep 30, 2024, Tandem Diabetes Care Inc's Depreciation & Amortization amounts to 16.4m USD.

What is Tandem Diabetes Care Inc's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 10Y
16%

Over the last year, the Depreciation & Amortization growth was 7%. The average annual Depreciation & Amortization growth rates for Tandem Diabetes Care Inc have been 6% over the past three years , 23% over the past five years , and 16% over the past ten years .

Back to Top